ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 541 entries already.
Hikma Pharmaceuticals today announces its Board of Directors has appointed Sigurdur (Siggi) Olafsson as Chief Executive Officer. Mr Olafsson will also join Hikma’s Board of Directors as an executive director, subject to election at the next annual general meeting in May 2018.
Addex Therapeutics, a leading company in allosteric modulation-based drug discovery and development, announced today the appointment of Jean-Philippe Rocher, PhD, as Co-Head of Discovery and Member of the Executive Management, effective 1 June 2018.
Selvita S.A., a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, announced today the appointment of Steffen Heeger, M.D., PhD, to the role of Chief Medical Officer.
In mid-November, the European Commission tabled the long-awaited review of its Bioeconomy Strategy and Action Plan. European Biotechnology spoke with Waldemar Kütt, Head of Unit Bioeconomy Strategy, about the development the bioeconomy has made since its launch in 2012 by the European Commission and the instruments needed to attract investments, make it circular, and create a stable policy environment for companies and investors.
Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, today appointed Dr. Ralf Otto as Chief Operating Officer (COO), effective February 1, 2018.
Storm Therapeutics today announced the appointment of Nobel Prize Winner Professor Thomas Cech as a Scientific Advisor. This appointment follows STORM Therapeutics’ successful Series A Financing Extension announced in January 2018.
Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. Based at the Company’s headquarters in Cambridge, UK, Dr Atkins also joins Congenica’s Board of Directors.
PharmaPack 2018:?The promises of digitalised medicine don’t stop at injection pens or autoinjectors. One of the early adopters in the field is Swiss Haselmeier AG (Pharmapack: hall 7.1, booth L19). European Biotechnology spoke with Paul E. Jansen, Member of the Board, from Haselmeier’s Boston office about how connected devices could define a new paradigm in therapy compliance and control of chronic diseases, and how they will shape the market.
BONESUPPORT (Nasdaq Stockholm: BONEX) announces that the Board of Directors has appointed Emil Billbäck as the new CEO of BONESUPPORT HOLDING AB. Mr. Billbäck has over 20 years management experience from the life science industry and the Board of Directors is of the opinion that he has the ideal profile to implement the Company’s strategy and to deliver shareholder value. He will join BONESUPPPORT on 1st March 2018 when he will replace Richard Davies who has been the Company’s CEO since January 2016.
Synpromics Ltd today announced the appointment of Sarah Haecker Meeks, PhD to the position of Vice President, Business Development.